Active Ingredient History

  • Now
BARACLUDE® is the tradename for entecavir, a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV). It inhibits all three steps in the viral replication process. By competing with the natural substrate deoxyguanosine triphosphate, entecavir functionally inhibits all three activities of the HBV polymerase (reverse transcriptase, rt): (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA. Upon activation by kinases, the drug can be incorporated into the DNA which has the ultimate effect of inhibiting the HBV polymerase activity. Entecavir is used for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.   NCATS

  • SMILES: NC1=NC2=C(N=CN2[C@H]3C[C@H](O)[C@@H](CO)C3=C)C(=O)N1
  • Mol. Mass: 277.2792
  • ALogP: -0.83
  • ChEMBL Molecule:
More Chemistry
  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$1.1929 - $45.9793


$1.8739 - $3.0472
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

anhydrous entecavir | anti-hbv placenta transfer factor | baraclude | bms-200475-01 | enecavir | entacavir | entecavir | entecavir anhydrous | entecavir (anhydrous) | entecavir hydrate | entecavir maleate | entecavir monohydrate | entecavirum | sq-34676


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue